| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3999652 | Urologic Oncology: Seminars and Original Investigations | 2015 | 6 Pages |
Abstract
Some clinical and molecular markers could improve the accuracy of residual tumor prediction at reTUR. Such a marker panel may help to identify patients with non-muscle-invasive bladder cancer who have residual tumor after first TUR and who may therefore benefit from reTUR.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Wentao M.D., Lin M.D., Xiongbin M.D., Yuan M.D., Wei M.D., Shiyu M.D., Minfeng M.D.,